Member Info for AndytheMKDon

Can't get a quote to either buy or sell even for a small amount of shares. Bit strange.

Looking to add at these prices as any positive news on Ck1, Tyk2 or a milestone payment will see a considerable increase.

SRRA need to p1ss or get off the pot as they will publish their financials soon which should make interesting reading.

Hey Aber, hope you're well.

Not the sort of news SRRA need to try and get the price above $1.00.. It should bring some focus to their plans for next steps in particular Chk1. Wouldn't it be nice if our stock markets did something similar to ensure shareholder value, however the AIM market wouldn't exist if rules like this applied, or maybe it might stop the MM's taking every stock price down at a whim as even they wouldn't be daft enough to see companies de-listed would they??

So on thin trading and a couple of sells they drop the price 6%.. !! AIM at it's best..

I'm selling all stocks I hold in AIM companies as the dice are so loaded it's beyond belief.. The only one I will retain is SAR and that's purely down to my belief that one day, just one day, our day in the sun will come. GLALTH's I think we're going to need it.

Oh, and on the AGM I will definitely be attending to wipe that smug cantankerous grin off Parkers face, shows how much he cares when he can't even get the names of products correct in his pitiful tweets..

This is aim, difficult to apply logic as news can often have little bearing on performance as we know all to well.

North Fork contract enabled them to get the placing away, once the placing shares are admitted to the market and the dust settles, the news will come on the contract and it will head back to 0.5p so the vultures can pick up their warrants at 0.49p.
I won't panic sell at this price as we all know the aim game..

Because this is the ces pit called the aim market!!

Despite better judgement I added more this morning. I won't quote "Buffet" type ballshyt we all know the lines.

I simply take a few givens and know the aim market from years of experience and the scars to prove it.

There will be price drivers in the future, we don't know when but we do know they will come:

1) We will receive a milestone for Chk1
2) Chk1 will be advanced to the next trials most likely with a Parp combo where suggestions are good results could be expected. (Chk1 is a real product backed by CRUK)
3) Tyk2 will be licensed or worst case taken into trials by CRUK.

The difference on the next occasions is when these spikes occur, I will sell take my profit and wait for a re-entry point, rather than what I have done in the past which was to build a position and hold it. Yes I might run the risk of missing out being out at the wrong times but at least my money would be in my bank rather than in the lap of the gods depending upon when the next time Tim Mitchel wants to return to the ATM to take out more of our money.

0.4p what a joke!!

90% buys today and no movement in sp, no wonder people are fed up with aim market.. For sure if we had 90% sells they would mark the price down.. feckers..!!

The sp was pushed down to 0.2p by a discount placing and is being held there now. Suddenly two big blocks of shares are declared in two days.. As somebody mentioned it would be strange if whoever has bought 8% through a spreadex company today is planning to short the stock so an assumption could well be these are long positions being taken up.. The question is at what price do they start to take profit?? The cynical side of me suspects these are positions being taken up to get resolutions through the agm.

Trades at 0.58 surely means the bid needs to be upped to 0.55 with the ask at 0.60.. Maybe then with a 10% rise and tighter spread we might see some traction. Fed up with this lowly price, when it's clear compounds such as ours are coming into demand and being acquired all around us, come on Parker get your bloody finger out.. gla. Andy.

My guess would be he bought them in the recent placing as the date of his declaration 18th June coincides with the admission of shares from the placing to the market yesterday morning.

are most likely rollover of T trades.

This mornings RNS was pretty pointless imo and was only a box-ticker for TM to say he has updated us regarding 1801 and 1802.. We can all read, and know well about Chk1 thanks to Sierra, so TM just regurgitating SRRA news isn't really news. Once again he alludes to milestone payments, why don't they just publish what the criteria are, surely that's written into a contract that as shareholders we have a right to know..?? As per usual the reason why Tim has a crack in his arse is so he can sit on a fence..
At least as Searle mentioned the seller / buyer seems to be done so no obstacles to a rise should something trigger one. Most likely news will be something happening regarding Sierra's future as they too seem to have a rather large crevasse in their derriere from fence sitting over their finances. gla. Andy. ;+)

There have been no trades since the 9M trade went through at 1.59pm.. Looks a bit odd or do the mm's want that 9M trade staring everybody in the face for an hour on their platforms for some reason..
Something has to break soon as this Mexican stand-off can't continue for ever..

Another 5M have just gone through at the same price of 0.385. grrrr !! Where's the nomad?? I have mailed them twice with no reply..

It simply means the trade went through at the mid price between the bid and the offer so it can't be determined if it is a buy or a sell. However, this is one of my pet hates as the market maker making the trade knows full well if it was a buy or a sell, they should be forced to disclose it's true identity.

Lets not forget Chk1 deal when ProNAi licensed it was US$326.00 Million. It's reasonable to expect the deal for Tyk2 to be multiples of this and to my knowledge we own 100% of 1801 and 1802.

Dr Tim Mitchell, CEO of Sareum, commented: "We are very pleased to have formally selected lead candidates from our TYK2 inhibitor programme for both cancer and autoimmune diseases. The candidates are distinct small molecules with attractive and highly competitive profiles for development in their respective indications. Both candidates have produced exciting results in preclinical disease models and we believe present valuable opportunities for licensing and/or further development. Our focus is now to advance both candidates into clinical studies, which we anticipate beginning in 2020."

.

Whilst agreeing with the frustration of the current impasse we have to recognise out destiny is not in our own hands.
Chk1 progress and milestones are in the control of Sierra and whilst we know Tyk2 is in the shop window it is totally dependant upon finding a suitor before the next steps can be made with 1801 and 1802. Just hoping it's like London buses that when one piece of news comes along the rest will follow. It will only take a milestone payment or a deal on Tyk2 to accelerate the share price and if either are substantial then the current sp will be a thing of the past. Here's hoping for something soon. gla. Andy. :+)